Welcome to our dedicated page for MapLight Therapeutics news (Ticker: MPLT), a resource for investors and traders seeking the latest updates and insights on MapLight Therapeutics stock.
MapLight Therapeutics, Inc. (Nasdaq: MPLT) is a clinical-stage biopharmaceutical company focused on debilitating central nervous system disorders, and its news flow reflects the progress of a multi-program CNS pipeline. Company announcements describe clinical trial milestones, regulatory designations, financial updates, and research collaborations tied to its circuit-focused drug discovery approach.
Recent news highlights include updates on Phase 2 studies such as ZEPHYR for schizophrenia and IRIS for autism spectrum disorder, along with the VISTA trial for hallucinations and delusions associated with Alzheimer’s disease psychosis. MapLight has reported accelerated enrollment in certain trials and provided guidance on expected timing for topline results, which are key events for investors and observers tracking the development of its product candidates.
The company has also disclosed that the U.S. Food and Drug Administration granted Fast Track designation to ML-007C-MA for Alzheimer’s disease psychosis, and that a Phase 1 study showed a generally favorable safety and tolerability profile in healthy elderly participants. In addition, MapLight has announced a strategic collaboration with SandboxAQ to apply AI-driven molecular simulation to novel G protein-coupled receptor targets for CNS disorders.
News items further cover MapLight’s initial public offering on the Nasdaq Global Select Market under the symbol MPLT, a concurrent private placement, and subsequent financial updates. Visitors to this page can review these press releases and other company communications to follow clinical progress, regulatory interactions, capital markets activity, and partnership developments related to MapLight’s CNS-focused pipeline.
MapLight Therapeutics (Nasdaq: MPLT) updated timing for topline results from two Phase 2 studies to Q3 2026. The Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia is enrolling ahead of schedule and is expected to randomize 300 hospitalized adult participants with acute psychosis. The Phase 2 IRIS trial of ML-004 for autism spectrum disorder has completed enrollment and randomized approximately 160 adult and adolescent participants. Both trials are double-blind, placebo-controlled. Management said accelerated enrollment allowed the company to narrow timing guidance to the third quarter of 2026.
MapLight Therapeutics (Nasdaq: MPLT) announced that the U.S. FDA granted Fast Track designation to ML-007C-MA for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
The company reported ML-007C-MA is an investigational M1/M4 muscarinic agonist with a generally favorable safety and tolerability profile in a Phase 1 study in healthy elderly participants. MapLight is enrolling a Phase 2 VISTA study planned for 300 participants and expects to report topline results in the second half of 2027. Fast Track may enable more frequent FDA interactions and potential accelerated pathways if criteria are met.
MapLight Therapeutics (Nasdaq: MPLT) and SandboxAQ announced a strategic collaboration on Dec 16, 2025 to discover and develop potential first‑in‑class therapies targeting a novel GPCR for central nervous system disorders. Under the agreement SandboxAQ received an upfront payment and is eligible for up to $200 million in preclinical, development, regulatory, and commercial milestone payments.
SandboxAQ will deploy large‑scale AI models and its AQBioSim molecular simulation platform to accelerate DMTA cycles; MapLight holds exclusive rights for potential clinical development and commercialization of collaboration compounds.
MapLight Therapeutics (Nasdaq: MPLT) reported third quarter 2025 results and program milestones on Dec 4, 2025. Key clinical timelines: ZEPHYR Phase 2 topline for ML-007C-MA in schizophrenia expected in H2 2026; VISTA Phase 2 topline for Alzheimer’s disease psychosis expected in H2 2027; IRIS Phase 2 topline for ML-004 in ASD expected in H2 2026. The company completed enrollment in IRIS (~160 participants) and nominated ML-009 for IND-enabling studies; ML-021 IND-enabling studies expected complete H2 2026. Financing: completed an IPO and private placement in Oct 2025 raising $296.5 million gross ($269.8 million net). Cash, cash equivalents and short-term investments were $227.2 million at quarter end, expected to fund operations through 2027.
MapLight Therapeutics (NASDAQ:MPLT) closed its initial public offering on Oct 29, 2025, selling 16,962,500 shares at $17.00 per share, which includes the underwriters' full exercise of an option to purchase an additional 2,212,500 shares.
MapLight also completed a concurrent private placement of 476,707 shares at the IPO price to affiliates of Goldman Sachs. Gross proceeds to MapLight from the IPO and private placement, before underwriting discounts, commissions and offering expenses, were $296.3 million. All shares were offered by MapLight and began trading on the Nasdaq Global Select Market on Oct 27, 2025 under the symbol MPLT. The registration statement became effective on Oct 25, 2025.
MapLight Therapeutics (NASDAQ: MPLT) priced its initial public offering of 14,750,000 shares at $17.00 per share and granted underwriters a 30-day option to buy up to 2,212,500 additional shares.
The company also announced a concurrent private placement of 476,707 shares to affiliates of Goldman Sachs at the IPO price. Gross proceeds from the IPO and private placement are expected to be approximately $258.9 million before underwriting discounts, commissions, and expenses. Shares are expected to begin trading on the Nasdaq Global Market on October 27, 2025 under symbol MPLT, with the offering expected to close on October 28, 2025 subject to customary closing conditions.
FAQ
What is the current stock price of MapLight Therapeutics (MPLT)?
What is the market cap of MapLight Therapeutics (MPLT)?
